Background: Amyloid ,3-protein (A,B), the major con-
INTRODUCTION
Alzheimer's disease is characterized by the deposition of amyloid (3-protein (AP3) in parenchyma and blood vessel walls and the intracellular accumulation of neurofibrillary tangles. A,B is derived by proteolysis of the larger ,B-amyloid precursor protein (,3PP), a 100-140 kDa integral membrane protein. Processing of ,3PP in the constitutive pathway results in the secretion of a large N-terminal soluble product (1PPj) and a membrane-retained C-terminal fragment of approximately 10 kDa (1) . Release of the N-terminal ectodomain of ,BPP results from cleavage by "a-secretase" an as yet unidentified protease that cleaves ,BPP within the AP3 sequence (2) .
Thus, formation of a full-length, 40-43 residue AP3 peptide is precluded by a-secretase proteolysis. Both intracellular and cell-surface ,3PP molecules are substrates for a-secretase; indeed, accumulating evidence suggests proteolysis of O3PP occurs in both cellular compartments (3) .
Generation and release of A,B from ,BPP occurs constitutively after two proteolytic events, designated ",3-and -y-secretase" cleavages at the AP3 N-and C-termini, respectively. In addition to I3PPS, Af3 and a 3-kDa fragment (p3) are normally produced and released from a variety of cells both in vivo and in vitro (4) . The (9, 10) . Acceleration of ,BPP metabolism through the a-secretory pathway by PKC activation results in a corresponding decrease in ,B-secretory processing and A,B production (1 1, 12 (6) . In pulse-chase experiments, confluent ,BPP-transfected CHO cells were labeled with 35S-methionine for 10 min and chased for 20 min or 2 hr with or without 1 ,uM phorbol-12,13-dibutyrate (PDBu). This labeling paradigm examines only the effect of PDBu on post-translational events. Immunoprecipitations of AP3 (media) and full-length ,BPP (cell lysates) were carried out with 1282, an antibody recognizing AP3, and a C-terminal antibody, CT15, respectively (14, 15) (Fig. 1) . O3PP, from media and saponin buffer (see below) were immunoprecipitated by antibodies B 5 (16) and 1736 (12) , which recognize the extracellular domain of OPP or a-secretase cleaved .PPs, respectively ( Fig. 1) .
To detect intracellularly cleaved IPPS, CHO cells pulse-labeled for 10 min were quickly chilled with ice-cold Dulbecco's phosphate buffered saline (DPBS) after a 10-or 20-min chase period. The cells were then incubated at 4°C for 40 min with 0.1% saponin in DPBS supplemented with protease inhibitors as described (17 (19) . Approximately 30% of cell surface molecules are eventually secreted into the medium ( Fig. 2A) . When PDBu is added at the beginning of the chase period, f3PP
secretion approximately doubled at each time point of the assay ( Fig. 2A) . This increase in ,BPP release correlated with a decrease in IPP internalization of -30% (Fig. 2B) . The characteristically short residence time of ,BPP on the cell surface was not altered by PDBu treatment (Fig. 2C ). (Fig. 3) . internalization after PKC activation (Fig. 2b) . However, by metabolic labeling with 35S-methionine, A,B release was inhibited by -80% (Fig. 3) , a result comparable to that reported by others (3). Therefore, when the production of AP3 is measured from total cellular O3PP labeled by 35S-methionine, PDBu inhibition of AP3 release is substantially greater than when only the cellsurface ,BPP pool is examined by selective surface radioiodination.
Cell Surface fPP after PDBu Treatment The above results suggest that the effect of PDBu on trafficking of cell-surface ,BPP molecules alone is insufficient to account for the overall decrease in AP3 production. Therefore, the amount of /3PP
on the cell surface after PDBu treatment was examined. As detected by surface radioiodination and immunoprecipitation, the level of cellsurface ,3PP was markedly decreased 15 min after the addition of PDBu (Fig. 4A) (Fig. 4B ). Since changes in endocytic trafficking are minor (Fig. 2) , in the range of 30%, this reduction in cell-surface O3PP must be due to other factors, in particular, to diminished sorting of molecules to the cell surface. Further evidence for this mechanism was provided by assaying for the arrival of ,BPP to the cell surface from newly synthesized molecules. Using this approach, the levels of cell-surface 3PP derived from newly synthesized molecules were dramatically decreased after PDBu treatment (Fig. 4C) . Specifically, treatment with PDBu for 10 to 20 min after the initial pulse labeling period resulted in -80-90% reduction in the amount of labeled cell-surface ,BPP. This experimental paradigm was such that the labeled molecules must have been newly synthesized and recently transported to the cell surface, in contrast to earlier experiments (Fig. 2, 4A and B) that examined the fate of the steady-state pool of O3PP already present at the cell surface when PDBu treatment was instituted. Thus, the latter pool is the summation of the decrease in nascent ,BPP arriving to the cell surface, as well as to the increase in I3PPS being released from the cell surface. O3PP to the cell surface in the secretory/exocytic pathway is altered, intracellular 3PPP was immunoprecipitated from saponin-treated CHO cells after treatment with PDBu using a pulse-chase paradigm. Treatment with low concentrations of saponin (0.1%) permeabilized but did not solubilize cell membranes because in control experiments, full-length ,BPP was virtually undetectable from the saponin buffer (Fig. 5A) . Therefore, predominantly soluble nonmembrane-bound 3PP molecules, i.e., ,PPs, were analyzed in this assay. As expected, secretion of .PPs into the medium was markedly increased by PDBu (Fig. 5B) (20) . The data presented here are consistent with the report that upon PKC activation, ,3PP is redistributed from the trans Golgi network (TGN) to other cellular locations through increased formation of secretory vesicles from the TGN (21). The results reported here complement this recent finding in demonstrating a large displacement of ,3PP away from the cell surface and an increase in the trafficking of fPP out of the cell. However, the data also demonstrated that the acceleration in a-secretase cleavage that accompanies this perturbation in O3PP sorting is only minimally increased at the plasma membrane. Therefore, a-secretase activity enhanced by PKC activation must occur in an intracellular compartment that remains to be defined (22) . Two potential mechanisms mediating this PKC effect come to mind: a direct PKC-mediated activation of intracellular a-secretase activity, or a displacement of fPP to the compartment where a-secretase is located.
Finally, in addition to phorbol esters, a number of other agents have been shown to both increase I3PPs secretion and decrease Af3 production (8) . These include treatment by cytokines, muscarinic activation, and inhibition of protein phosphatases. In view of the multiple effects of PKC activation by PDBu on IPP trafficking and processing, one would hypothesize that the other agents will show a range of cellular alterations affecting ,3PP and A,B production and release. Understanding the multitude of cellular perturbations that alter I3PP trafficking should generate additional potential targets for inhibiting A,B generation.
